A5026112588- Pancreatic and Hepatic Oncology Research
- Phagocytosis and Immune Regulation
- Renal and related cancers
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Cell Adhesion Molecules Research
- Epigenetics and DNA Methylation
- Protein Tyrosine Phosphatases
- Ferroptosis and cancer prognosis
- interferon and immune responses
- Microtubule and mitosis dynamics
- Cellular Mechanics and Interactions
- Cancer, Hypoxia, and Metabolism
- Machine Learning in Healthcare
- Blood Pressure and Hypertension Studies
- Isotope Analysis in Ecology
- Angiogenesis and VEGF in Cancer
- Cancer Immunotherapy and Biomarkers
- Healthcare Technology and Patient Monitoring
- Lung Cancer Treatments and Mutations
- Nutritional Studies and Diet
- Time Series Analysis and Forecasting
- Heart Rate Variability and Autonomic Control
- Melanoma and MAPK Pathways
- Advanced Chemical Sensor Technologies
Clinica Universidad de Navarra
2021-2025
Universidad de Navarra
2021-2023
Indian Institute of Science Bangalore
2020-2021
Boston Scientific (United States)
2020
PES University
2017
The identification of pancreatic ductal adenocarcinoma (PDAC) dysregulated genes may unveil novel molecular targets entering inhibitory strategies. Laminins are emerging as potential in PDAC given their role diagnostic and prognostic markers. Here, we investigated the cellular, functional, clinical relevance LAMC2 its regulated network, with ultimate goal identifying therapies.LAMC2 expression was analyzed tissues, a panel human mouse cell lines, genetically engineered model. Genetic...
Tumor organoids are powerful tools to study cancer. However, the clinical translation of organoid-based studies depends on how closely organoid scaffolding material recapitulates tumor extracellular matrix (ECM). We present a quantitative analysis effect scaffold composition phenotype, tissue remodeling, metabolism, and drug resistance pancreatic ductal adenocarcinoma (PDAC) organoids. grew PDAC within hydrogels made Matrigel, collagen-I, or mixture collagen-I Matrigel. Our results show that...
Drug combinations are key to circumvent resistance mechanisms compromising response single anti-cancer targeted therapies. The implementation of combinatorial approaches involving MEK1/2 or KRASG12C inhibitors in the context KRAS-mutated lung cancers focuses fundamentally on targeting KRAS proximal activators effectors. However, antitumor effect is highly determined by compensatory arising defined cell types tumor subgroups. A potential strategy find drug a larger fraction may capitalize...
Ovarian cancer metastasizes into peritoneum through dissemination of transformed epithelia as multicellular spheroids. Harvested from the malignant ascites patients, spheroids exhibit startling features organization typical to homeostatic glandular tissues: lumen surrounded by smoothly contoured and adhered epithelia. Herein, we demonstrate that cells specific ovarian lines in suspension, aggregate dysmorphic solid “moruloid” clusters permit intercellular movement, cell penetration,...
High blood pressure (BP) is a major risk factor for cardiovascular disease (CVD). Consumption of dark chocolate, which high in flavonoids that may reduce CVD risk, an attractive intervention to BP. Additionally, the use mobile health (mHealth) technologies (eg, telehealth, smartphones, and wearable devices) can improve outcomes patients with CVD.The purpose this study was investigate impact chocolate intake on BP, subject mHealth, integration mHealth into clinical trial.The COCOA-BP...
<div>AbstractPurpose:<p>The identification of pancreatic ductal adenocarcinoma (PDAC) dysregulated genes may unveil novel molecular targets entering inhibitory strategies. Laminins are emerging as potential in PDAC given their role diagnostic and prognostic markers. Here, we investigated the cellular, functional, clinical relevance LAMC2 its regulated network, with ultimate goal identifying therapies.</p>Experimental Design:<p>LAMC2 expression was analyzed tissues, a...
<div>AbstractPurpose:<p>The identification of pancreatic ductal adenocarcinoma (PDAC) dysregulated genes may unveil novel molecular targets entering inhibitory strategies. Laminins are emerging as potential in PDAC given their role diagnostic and prognostic markers. Here, we investigated the cellular, functional, clinical relevance LAMC2 its regulated network, with ultimate goal identifying therapies.</p>Experimental Design:<p>LAMC2 expression was analyzed tissues, a...
<p>Suppl. Figure 3. A. Immunoblot of LAMC2 upon Lamc2 knockdown by a specific shRNA in 511950 and PM12167 PDAC mouse cell lines. B. Quantification organoid number lines.C. area (AU) same lines as Error bars correspond to s.d. D. HPAFII line. E. line expressing TET-inducible against (bottom) or control (top) cultured 3D. F. Representative images the subcutaneous tumors from PATU8902 cells at sacrifice. G. H I. IHC expression (H) (I) sacrifice J. derived intrapancreatic injection K. L M....
<p>Suppl. Figure 1. A. Association analysis of LAMC2 expression with clinical variables using quartile 1 H score (23.2) as cut-off. B. Correlation and tumor volume in a tissue array 119 PDAC samples. C D. Survival stratified by from ICGC TCGA datasets.</p>
<p>Suppl. Figure 2. A. LAMC2 immunoblot in HPAFII after knockdown using 2 different sgRNAs. B. Cell proliferation assessed by MTS Error bars correspond to s.d. C. PM12167 shRNA mediated Lamc2 knockdown. D. E. Colony forming ability F. MTS, shRNA-mediated PATU8902 and PDAC cell lines a tet-inducible system. s.d.</p>
<p>Suppl. Figure 1. A. Association analysis of LAMC2 expression with clinical variables using quartile 1 H score (23.2) as cut-off. B. Correlation and tumor volume in a tissue array 119 PDAC samples. C D. Survival stratified by from ICGC TCGA datasets.</p>
<p>Suppl. Figure 3. A. Immunoblot of LAMC2 upon Lamc2 knockdown by a specific shRNA in 511950 and PM12167 PDAC mouse cell lines. B. Quantification organoid number lines.C. area (AU) same lines as Error bars correspond to s.d. D. HPAFII line. E. line expressing TET-inducible against (bottom) or control (top) cultured 3D. F. Representative images the subcutaneous tumors from PATU8902 cells at sacrifice. G. H I. IHC expression (H) (I) sacrifice J. derived intrapancreatic injection K. L M....
<p>Suppl. Figure 5. A. RNA expression of KRAS, AREG, DUSP6 and FOSL1 in PATU8902 HPAFII cells expressing a TET-inducible KRAS shRNA or control shRNA. B. Box whiskers plot showing Mean Fluorescence Intensity (MFI) Areg, Dusp6, Fosl1 upon KRas inactivation iKRAS GEM. Error bars correspond to s.d. C. Heat map downregulated genes tet-inducible LAMC2 compared group (shRNA GFP). D. mRNA E. overlapping (LAMC2 -ctrl-, FGFBP1, HMGA1, AURKA, HMMR, PLK1, SNAI2 PITPNC1) F. Protein phospho-ERK,...
<p>Suppl. Figure 6. A. Left. Protein expression levels of phospho-ERK and ERK in HPAFII PATU8902 cells treated with MEKi (50 nM) for 24 h. Right. phospho-AXL AXL AXLi (0.2 μM) Quantification: pAXL normalized to total housekeeping protein levels. B. Heatmap the Fa fraction CAPAN2 PDAC human cell line single MEKi, AXLi, or both at indicated concentrations 72 C. 2D surface plot Bliss synergy scores from Red regions indicate synergistic interactions.</p>
<p>Suppl. Figure 7. A. KRAS, TP53, SMAD4 genetic alteration in the 2 PDO characterized by DNA sequencing.</p>
<p>This file includes the Suppl. Methods, Table (1) and References</p>
<p>This file includes the Suppl. Methods, Table (1) and References</p>
<p>Suppl. Figure 5. A. RNA expression of KRAS, AREG, DUSP6 and FOSL1 in PATU8902 HPAFII cells expressing a TET-inducible KRAS shRNA or control shRNA. B. Box whiskers plot showing Mean Fluorescence Intensity (MFI) Areg, Dusp6, Fosl1 upon KRas inactivation iKRAS GEM. Error bars correspond to s.d. C. Heat map downregulated genes tet-inducible LAMC2 compared group (shRNA GFP). D. mRNA E. overlapping (LAMC2 -ctrl-, FGFBP1, HMGA1, AURKA, HMMR, PLK1, SNAI2 PITPNC1) F. Protein phospho-ERK,...
<p>Suppl. Figure 7. A. KRAS, TP53, SMAD4 genetic alteration in the 2 PDO characterized by DNA sequencing.</p>
<p>Suppl. Figure 2. A. LAMC2 immunoblot in HPAFII after knockdown using 2 different sgRNAs. B. Cell proliferation assessed by MTS Error bars correspond to s.d. C. PM12167 shRNA mediated Lamc2 knockdown. D. E. Colony forming ability F. MTS, shRNA-mediated PATU8902 and PDAC cell lines a tet-inducible system. s.d.</p>
<p>Suppl. Figure 6. A. Left. Protein expression levels of phospho-ERK and ERK in HPAFII PATU8902 cells treated with MEKi (50 nM) for 24 h. Right. phospho-AXL AXL AXLi (0.2 μM) Quantification: pAXL normalized to total housekeeping protein levels. B. Heatmap the Fa fraction CAPAN2 PDAC human cell line single MEKi, AXLi, or both at indicated concentrations 72 C. 2D surface plot Bliss synergy scores from Red regions indicate synergistic interactions.</p>
<p>Suppl. Figure 4. A. Correlation plot of mRNA expression levels LAMC2 and AXL in the PDAC human data set from ICGC. B. TCGA.</p>